Eli Lilly Confirms 2010 Outlook

There’s good news from Lilly (LLY), although the market isn’t taking it that way. The company said it expects to earn $4.65 to $4.85 next year. That’s pretty good considering the stock is currently under $35.
The problem for Lily is that several of their top drugs come off patent over the next few years. They’ve said that they plan to introduce two new drugs a year starting in 2013. Bloomberg reports: “Lilly said it has more than 60 drugs in clinical development and expects in 2011 to have 10 medicines in the final stage of trials generally required for U.S. approval.”

Posted by on December 10th, 2009 at 10:36 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.